Cargando…

Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept

Detalles Bibliográficos
Autores principales:	Duret, Pierre-Marie, Sebbag, Eden, Mallick, Auriane, Gravier, Simon, Spielmann, Lionel, Messer, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456545/ https://www.ncbi.nlm.nih.gov/pubmed/32354772 http://dx.doi.org/10.1136/annrheumdis-2020-217362

Ejemplares similares

The crossbow sign in extracranial giant cell arteritis
por: Duret, Pierre‐Marie, et al.
Publicado: (2021)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

Acute Q Fever in an Ankylosing Spondyloarthritis Patient Treated with Etanercept
por: Guiga, A., et al.
Publicado: (2021)

Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
por: Felten, Renaud, et al.
Publicado: (2023)

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis
por: Liu, Jing, et al.
Publicado: (2016)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C‐Reactive Protein Levels
por: Tam, Hoi Ki Joshua, et al.
Publicado: (2021)

Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat
por: Widawski, L., et al.
Publicado: (2022)

Continuous Use of Etanercept During Pregnancy Does Not Affect TNF-Alpha Levels in Umbilical Cord Blood
por: Nishide, Masayuki, et al.
Publicado: (2022)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy
por: Sebastian, Agata, et al.
Publicado: (2017)

Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2021)

Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor
por: Lan, Joung-Liang, et al.
Publicado: (2017)

Microbiota Composition May Predict Anti-Tnf Alpha Response in Spondyloarthritis Patients: an Exploratory Study
por: Bazin, Thomas, et al.
Publicado: (2018)

Addition of a Viral Immunomodulatory Domain to Etanercept Generates a Bifunctional Chemokine and TNF Inhibitor
por: Alejo, Alí, et al.
Publicado: (2019)

Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α
por: Puertas-Abreu, Eduardo, et al.
Publicado: (2012)

Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000)

Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis
por: Kahn, Robin, et al.
Publicado: (2016)

Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
por: Gratacós, Jordi, et al.
Publicado: (2019)

Spondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors
por: Moz, Stefania, et al.
Publicado: (2017)

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
por: Manica, Santiago Rodrigues, et al.
Publicado: (2020)

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study
por: Lubrano, Ennio, et al.
Publicado: (2020)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial
por: Proft, Fabian, et al.
Publicado: (2021)

Ulcerative Colitis-associated Spondyloarthritis Successfully Treated with Infliximab in the Absence of Enhanced TNF-α Responses
por: Fujita, Shunsuke, et al.
Publicado: (2022)

Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2021)

Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis
por: Hiltunen, J., et al.
Publicado: (2021)

Characterisation of gut microbiota composition in patients with axial spondyloarthritis and its modulation by TNF inhibitor treatment
por: Vallier, Marie, et al.
Publicado: (2023)

Influence of TNFα–308 and T676G TNF-RII polymorphism on response to etanercept and posibility to discontinue tretment
por: Vojinovic, J, et al.
Publicado: (2011)

Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
por: Soubrier, Martin, et al.
Publicado: (2018)

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study
por: Maksymowych, Walter P, et al.
Publicado: (2016)

Long-Term Adherence to Etanercept in Treatment Effectiveness of Patients with Spondyloarthritis: 7-Year Data from the Iraq National Registry
por: Younis, Ali Abdulrahman, et al.
Publicado: (2022)

Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis
por: Paramarta, Jacqueline E, et al.
Publicado: (2011)

Relative overexpression of membrane-bound versus soluble TNF in spondyloarthritis
por: Ambarus, Carmen A, et al.
Publicado: (2012)

Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs
por: Chan, Shirley Chiu Wai, et al.
Publicado: (2021)

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2019)

Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study
por: Van Rossen, Liz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e2hvmvf2j2r3gq2luqi41k46r1